00:00 / 00:00
HORMONES & HORMONE MODULATORS for CANCER TREATMENT, PART 1/2 | |||
DRUG NAME | hydroxyprogesterone (Duralutin), medroxyprogesterone (Depo-Provera), megestrol (Megace) | tamoxifen (Nolvadex), raloxifene (Evista), toremifene (Fareston) | anastrozole (Arimidex), letrozole (Femara), exemestane (Aromasin) |
CLASS | Sex hormones | Selective estrogen receptor modulators (SERMs) | Aromatase inhibitors |
MECHANISM of ACTION | Suppress gonadotropin release by the pituitary → block sex hormone production by the gonads | Block estrogen receptors on cancer cells | Reduce estrogen production |
INDICATIONS |
| ||
ROUTE(S) of ADMINISTRATION |
|
| |
SIDE EFFECTS |
| ||
CONTRA-INDICATIONS & CAUTIONS |
|
HORMONES & HORMONE MODULATORS for CANCER TREATMENT, PART 2/2 | ||
DRUG NAME | flutamide (Eulexin), apalutamide (Erleada), bicalutamide (Casodex, Calutex) | leuprolide (Eligard, Lupron, Viadur), goserelin (Zoladex) |
CLASS | Antiandrogens | Gonadotropin-releasing hormone analogs |
MECHANISM of ACTION | Block androgen receptors on cancer cells | Reduce gonadotropin release by the pituitary → block sex hormone production by the gonads |
INDICATIONS |
| |
ROUTE(S) of ADMINISTRATION |
|
|
SIDE EFFECTS |
| |
CONTRAINDICATIONS & CAUTIONS |
|
NURSING CONSIDERATIONS for HORMONES & HORMONE MODULATORS for CANCER TREATMENT | ||
ASSESSMENT & MONITORING | Assessment and monitoring: Tamoxifen for ductal carcinoma in situ Assessment
Monitoring
| |
CLIENT EDUCATION |
|
Hormones and hormone modulators are a group of medications that suppress the function of specific hormones, which slows or stops the growth of hormone-dependent cancers, such as breast, endometrial, and prostate cancers. They can also be used to ease the symptoms caused by certain types of cancer, such as brain or renal cancers.
Now, hormones and hormone modulators can be broadly classified as sex hormones; antiestrogens; aromatase inhibitors; antiandrogens; and gonadotropin-releasing hormone analogs.
Now, some commonly used sex hormones include hydroxyprogesterone, which is administered intramuscularly or subcutaneously for advanced uterine adenocarcinoma; as well as medroxyprogesterone, and megestrol, which are taken orally for endometrial or breast cancer. Once administered, these medications work by suppressing the pituitary gland from releasing gonadotropins, so follicle-stimulating hormone or FSH for short, and luteinizing hormone or LH. As a result, gonadotropins aren’t available to stimulate sex hormone production by the gonads, which ultimately delays the growth of sex hormone-dependent tumors.
There are also antiestrogens, which include selective estrogen receptor modulators, or SERMs for short, such as tamoxifen, raloxifene, and fulvestrant. These medications are administered orally, and work by blocking estrogen receptors on cancer cells, which delays the growth of estrogen-dependent tumors.
Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Cookies are used by this site.
USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.